



Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine?

Iacopo Chiodini^{1,2*} and Luigi Gennari³

¹ Department of Endocrine and Metabolic Diseases, IRCCS, Istituto Auxologico Italiano, Milan, Italy, ² Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy, ³ Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy

Keywords: glucocorticoid, aldosterone, glucocorticoid receptors, cortisol, 11 β -hydroxysteroid dehydrogenase, paraganglioma-pheochromocytoma

INTRODUCTION

In recent years, more and more evidence has emerged on the deleterious systemic effects arising from adrenal hormone alterations, even if mild and/or asymptomatic. On the other hand, an increased prevalence of adrenal diseases has been reported in patients without signs and symptoms specific of adrenal disorders but affected by chronic diseases or conditions (ie diabetes, hypertension, osteoporosis, depression, fibromyalgia, hypotension) that are often misdiagnosed as ‘idiopathic’ but which should instead be attributed to observed alterations in adrenal function (1–7). Such an expansion in knowledge of the role of adrenal hormones in the pathophysiology of common human diseases is in accordance with well-known evidence arising from studies in mammals that adrenal hormones influence several functions, including different metabolic pathways, immune responses, cognition, circadian rhythms, saline homeostasis, blood pressure control and stress response (8). However, more recently, not only has the degree of secretion of adrenal hormones been suggested, but also their metabolism and sensitivity within peripheral target tissues have been suggested to play a role in the development of chronic disorders such as hypertension, diabetes, osteoporosis, and mood disorders, even in subjects with biochemically normal adrenal function (9–18).

Therefore, since occult adrenal hormone dysfunction can occur in some categories of patients, recent research has focused on the screening of adrenal disorders among subjects affected by bone fragility, hypertension, and type 2 diabetes (2, 4). However, the aftermath of a wide screening is the finding of false positive results, with potential economic and psychological consequences for health care systems and the patients, respectively (19). Thus, optimizing the accuracy of screening tests has been advocated in order to avoid overdiagnosing and to individuate true positive cases. In this sense, recent findings that various adrenal disorders have a genetic basis and that genetic variants may predispose to the development of these diseases could lead to a better focus on providing screening tests to the individuals at risk (20–23).

The path toward precision medicine in adrenal endocrinology has just begun (24) and the future challenges for its further development should be addressed to the following questions: i) when to suspect and who to screen for adrenal dysfunctions; ii) what and how to measure to reliably diagnose adrenal diseases; iii) how to search for adrenal hormone secreting lesions; iv) how and what can cure patients with adrenal disorders.

OPEN ACCESS

Edited and reviewed by:

Jeff M. P. Holly,
University of Bristol, United Kingdom

*Correspondence:

Iacopo Chiodini
iacopo.chiodini@unimi.it
orcid.org/0000-0001-7594-3300

Specialty section:

This article was submitted to
Adrenal Endocrinology,
a section of the journal
Frontiers in Endocrinology

Received: 25 July 2021

Accepted: 09 August 2021

Published: 03 September 2021

Citation:

Chiodini I and Gennari L (2021) Grand Challenge in Adrenal Endocrinology: Is the Legacy of the Past a Challenge for the Future of Precision Medicine? *Front. Endocrinol.* 12:747006. doi: 10.3389/fendo.2021.747006


WHEN TO SUSPECT AND WHO TO SCREEN FOR ADRENAL DISEASES

In the past, screening for disorders due to altered adrenal hormone secretion was reserved for patients with specific signs and symptoms, such as plethora, striae rubrae, buffalo hump, and hypertrichosis (patient 1, **Figure 1**). This traditional approach prevails in the practices of many physicians since the idea that individuals without overt signs and/or symptoms of adrenal dysfunction could be affected by adrenal disorders is scarcely accepted by the vast majority of experts in the field. However, in recent years several reports have described the presence of occult alterations in adrenal hormone secretion in patients with nonspecific conditions (such as hypertension, osteoporosis, diabetes, mood disorders) or nonspecific symptoms (fatigue, anorexia, weight loss, hypotension, hyponatremia, and hyperkalemia) (4, 25) (patients 2, **Figure 1**). This difficulty in turning the observation point upside down has caused that, to date, no widely accepted guidelines are available in order to improve the diagnosis of occult adrenal dysfunction. As a consequence, scarce data are available on the true prevalence of adrenal causes of some chronic diseases and conditions, such as the above-mentioned ones.

For example, the available guidelines consider it mandatory to screen for occult adrenal hormone hypersecretion in hypertensive patients in the presence of specific characteristics of hypertension even in the absence of typical symptoms of adrenal disorders (5, 26, 27). Notwithstanding these indications, few studies have been conducted to date to assess the prevalence of hypercortisolism in hypertensive patients. Importantly, in patients with hypercortisolism,

normalizing cortisol secretion generally improves or even normalizes blood pressure (28). In contrast, no guidelines have been provided for the detection of hypercortisolism in patients with diabetes or osteoporosis, despite several studies reporting an unexpected increased prevalence of subtle excess cortisol excess in these patients (2, 29). Currently, we only have some expert opinions suggesting that patients with poorly controlled diabetes or complicated controlled diabetes and hypertension, as well as patients with unexplainable bone fragility or severe osteoporosis, should be screened for hypercortisolism (2, 30, 31). Consistent with the hypothesis of a current underestimation of the number of patients with adrenal diseases, the incidence of paraganglioma (PGL) has increased 4.8 times from 1977 to 2015, which is likely due to its recognition in patients with PGL found in small incidentally discovered adrenal masses and few or no paroxysmal symptoms (22). This finding suggests that current guidelines, based on old data, may not be adequate to detect patients with PGL seen in daily clinical care today. Likewise, despite some expert opinions, no guidelines suggest screening for primary adrenal insufficiency in cases of asthenia, weight loss, dehydration, hypotension, fever, abdominal pains, nausea, and hyperpigmentation or patients with type 1 diabetes, autoimmune thyroid disease, unexplained collapse, hypotension, vomiting or diarrhoea (4).

More recently, adrenals, and in particular the hypothalamic-pituitary-adrenal axis (HPA) have been identified as a likely target of immune therapies and checkpoint inhibitor therapies in patients with cancers (32). Most patients present with nonspecific symptoms, such as fatigue, which can be erroneously attributed to the malignant disease itself. However, up to 6% of patients treated with these drugs may experience hypophysitis and possible disruption of the HPA axis



or primary adrenal insufficiency (32), which are two well-known life-threatening conditions. Therefore, in the future, screening for adrenal or HPA activity disorders should become a routine practice for oncologists using these therapies, even in the absence of specific signs and symptoms for adrenal insufficiency.

WHAT AND HOW TO MEASURE

Nowadays, the diagnosis of adrenal diseases is somehow hindered by the cornerstones achieved in the past (e.g. concerning the metabolites to be measured, the methods to use, and the cut-offs to apply). Indeed, what we have inherited from old literature, seems to quickly become a legacy to overcome rather than supporting pillars to rely on. For example, several studies suggest that the cutoff of cortisol after 1 mg overnight dexamethasone suppression test to diagnose hypercortisolism (i.e. 1.8 µg/dL) might not be sufficiently sensitive and that lower cut-offs might be adopted (33–36). Paradoxically, some guidelines still advocate even higher cut-off points for diagnosing autonomous cortisol excess (37). Furthermore, nowadays, several pieces of evidence point to the limited reliability of some methods for measuring cortisol secretion (i.e. salivary cortisol and urinary free cortisol) in patients with possible occult hypercortisolism (38), but these tests are still used due to the low sensitivity of endocrinologists for diagnosing subtle excess cortisol. As a consequence, many patients with hypercortisolism have been left undiagnosed until now (2). Similarly, the recent introduction of more specific cortisol assays results in lower cortisol concentrations and this may increase the number of patients diagnosed with adrenal insufficiency. The medical community should quickly adopt the new criteria, as this could lead to misdiagnosis and overtreatment in patients suspected of hypocortisolism (39).

The limited specificity due to cross-reaction with endogenous steroids of the traditionally used cortisol immunoassays results in limited precision and high variability between laboratories. Recently, liquid chromatography tandem mass spectrometry (LC-MS/MS) measurements of cortisol in saliva and urine have been shown to eliminate the influence of the cross-reactivity with cortisone and other steroids, thus providing higher specificity as compared with immunoassays. In patients with suspected hypercortisolism, the use of LC-MS/MS increases specificity, thus reducing the number of false positive results. On the other hand, since in patients with hypercortisolism the clinical picture may also depend on the secretion of steroid precursors, paradoxically, the sensitivity for Cushing syndrome detection may be similar, if not higher, for many immunoassays already in use than for LC-MS/MS. However, this latter method could be useful in the suspicion of factitious hypercortisolism, in establishing whether the achieved level of dexamethasone is appropriate for DST, in the diagnosis of polycystic ovarian syndrome (40) and in medically treated patients with Cushing's syndrome (41). However, again in these patients, measuring cortisol and its metabolites by immunoassay could be more representative of real glucocorticoid (GC) secretion and,

possibly more predictive of clinical outcomes, than measuring only pure cortisol levels by LC-MS/MS. Therefore, the use of LC-MS/MS measurement of a comprehensive steroid profile, rather than cortisol alone, could be proposed for the detection of subtle excess GC in patients with incidentally discovered adrenal masses (42, 43). In addition, 11-deoxycortisol in serum or urine could become a sensitive marker of residual adrenal function in the future. Indeed, thanks to the use of the LC-MS/MS measure of the steroid metabolome, residual adrenal function has been suggested to be present in up to 30% of patients with Addison's disease (44). Finally, the possibility of measuring cortisol and cortisone with LC-MS/MS can consent to evaluate the degree of peripheral activation of cortisone in cortisol, which could become an important marker to evaluate the cortisol milieu in the individual patient (14, 45). Other methods for measuring cortisol will probably be available, such as surface-enhanced Raman spectroscopy, in addition to immunoassay, which has recently been suggested to be even better than LC-MS/MS in terms of sensitivity for *in situ* monitoring of human stress levels and cortisol-related disorders (46).

Long-standing exposure to an excess or deficiency of glucocorticoids is a likely explanation for the lack of signs and symptoms in more and more patients with hypercortisolism or hypocortisolism, respectively. Along with the advantages of being noninvasive methods that do not require special storage conditions, the use of hair or nail samples to assess cortisol concentration has the important advantage of giving retrospective information about the accumulation of cortisol, allowing for the evaluation of cortisol secretion in the long term. Although to date, this information is available mainly on stress disorders, in the future, the use of hair and nail cortisol determination could become important even for the evaluation of patients with hypercortisolism or hypocortisolism (47–49).

The genetic approach to the diagnosis of adrenal disease will probably be used more and more in the future. For example, evaluating the genetic variants of the GC receptor (18) and the 11β-hydroxysteroid dehydrogenase enzymes (50) could consent to predict the risk of being affected by some cortisol-related disorders (51). Already now, the search for genetic mutations in patients with Addison's disease or PGL has become extremely important for possible implications and genetic counseling (52–55) and similar data are coming even regarding functioning adrenocortical adenomas (21, 55). In patients with aldosterone-producing adenoma, associations have also been proposed between histology, genotype, race, gender, and clinical characteristics, suggesting the need to consider several aspects together to improve the clinical management of these patients (56, 57).

HOW TO SEARCH

An everyday challenge for adrenal endocrinologists is to assess: i) when to functionally characterize an adrenal mass (particularly if incidentally found); ii) how to detect very tiny lesions or to distinguish between benign and malignant adrenal lesions; and

iii) how to find an extra-adrenal source of an excess adrenal hormone. These difficulties are common challenges in patients with suspected adrenocortical carcinoma (ACC), extra-adrenal or metastatic PGL, or primary aldosteronism (PA). We have become used to characterizing adrenal tumors by measuring Hounsfield units and contrast wash out by computed tomography (CT) and chemical shift with magnetic resonance imaging (MRI), respectively, in selected patients. In case of doubt about possible malignancy, 18F-fluorodeoxyglucose (FDG) positron emission tomography (18FDG-PET) may be helpful, as adrenal carcinomas are generally, but not invariably, 18FDG-PET positive. Therefore, new radiotracers are needed for a more accurate diagnosis, possibly based on the new acquisitions on metabolomics (58).

Recently, the European Association of Nuclear Medicine has provided indications on the use of CT/MRI or [68Ga] Ga-DOTA-SSA PET/CT or [18F] FDOPA to assess an adrenal or extra-adrenal mass suspicious for adrenal PGL. These experts agreed on the need to choose these methods based on genetic characterization (i.e. HIF2A/VHL/MAX, SDHB mutations) (59, 60). Finally, 11C-metomidate, an inhibitor of 11- β -hydroxylase, has been found to be highly specific for adrenocortical masses and a potentially useful PET tracer for the identification of PA and ACC. These recent advances can provide two lessons to be learned. First, in the future, the introduction of new radiopharmaceuticals, especially those with theranostic potential, together with a better genetic characterization of adrenal tumors will change the landscape and will enable individualized treatment schemes to achieve higher responses while reducing toxicity. Second, obtaining consensus and setting up networks among experts will allow patients to discuss their clinical cases in multidisciplinary teams for better clinical management.

HOW AND WHAT TO CURE

Historically, the cure of adrenal disorders includes two equally important issues: the treatment of hormonal alteration and the treatment of adrenal disease-related comorbidities. The new challenge is to be aware that these issues are important in all patients with adrenal disorders, not only in severe cases, and that the coexistence of certain risk factors or complications can influence treatment decisions (61).

For example, surgery remains the definitive cure for patients with unilateral adrenal functioning tumor, but today more and more patients are diagnosed with bilateral adrenal lesions and/or are not feasible for surgical procedures due to advancing age or high risk of surgical complications. These patients need to be treated medically. In patients with adrenal hypercortisolism, as now, medical therapy includes adrenal steroidogenesis inhibiting agents (eg ketoconazole, metyrapone, mitotane, etomidate) and GC receptor blocker (mifepristone). New steroidogenesis inhibitors (i.e., osilodrostat) and other GC receptor antagonists with less adverse effects compared to mifepristone are in clinical trials (relacorilant) and a new drug is being developed, ATR-101, which exerts its action on cholesterol acyltransferase 1, a transmembrane enzyme involved in cholesterol metabolism

(62, 63). Since the steroidogenesis inhibitors act on adrenal enzymes on multiple levels with different selectivity, potency, and onset of action, sequential/combination schemes may be considered in the future in some patients. Here, the first challenge is to choose the best drug for individual patients. Second, steroidogenesis inhibitors are titrated to normalize urinary free cortisol, but with GC receptor antagonists, as now, it is not possible to biochemically evaluate the drug effect, which can only be assessed clinically. Third, the goal of controlling hormonal hypersecretion must be achieved by avoiding the risk of overtreatment, which may be as deleterious as the disease itself. This is a common problem even in patients with congenital adrenal hyperplasia, in whom the amount of GC used to inhibit ACTH could lead to overtreatment. In these patients, the combination of GC at lower doses with nonsteroidal and selective corticotroph releasing hormone receptor antagonists could prove to be effective in controlling androgen secretion (64). Finally, increasing the selectivity of steroidogenesis enzymes is another goal in the field of adrenal endocrinology. In PA, new non-steroidal mineral-corticoid antagonists, selectively targeting aldosterone synthesis, which are more specific than spironolactone and more potent than eplerenone, are currently under development. Even for PA patients, future challenges will be to find new targets for medical therapy based on genetic studies. Based on the discovery of recurrent mutations in genes encoding ion channels in PA, new perspectives are opening for targeted therapy for patients carrying specific mutations, and, paradoxically, some old drugs that act on calcium and sodium channels, such as macrolide antibiotics, verapamil, and amiloride, could live a new life (57).

The challenge of preselecting patients to personalize therapy must be played particularly in patients with advanced adrenal cancer (ACC) or with metastatic PGL. For ACC, chemotherapy has limited efficacy and the clinical utility of available targeted therapies alone or in combination with immune checkpoint inhibitors has been shown to be scarce. However, some case reports suggest that certain patients have experienced clinical benefits with these therapies. Furthermore, it is possible that in these patients elevated levels of GC limit the efficacy of these agents. Here, the challenge is to develop biomarkers that predict which patient would have the greatest benefit to immunotherapies (65). For patients with metastatic PGL, therapy with 131I-metaiodobenzylguanidine is already used in selected cases. As discussed above, the genetic background of patients with PLG is complex, but the genetic expression profile could be useful to guide the choice of radiopharmaceutical treatment (53).

Despite the recent development of new modes of GC delivery that could improve quality of life in some patients with adrenal insufficiency, and although further therapy options will probably be available in the future, current treatment is not curative, but simply attempts to replace physiological cortisol concentrations. Therefore, the real challenge would be stopping and possibly reversing autoimmune destruction. Studies using rituximab or using chronic stimulation by adrenocortical releasing hormone stimulation have been shown to reactivate adrenocortical function in some patients (44). The production of autologous

stem cells and transplantation of adrenocortical tissue are other promising approaches. Again, in the future, a deeper understanding of the pathophysiology of adrenal insufficiency could contribute to the development of tissue engineering strategies and the delivery of regenerative therapies.

Research should focus on the therapy of adrenal disorders and be directed to consider the possible and previously not considered consequences of adrenal hormone alterations. Recently, the issue of quality of life (QoL) and long-term psychosocial consequences have received increased attention. Patients with both hypercortisolism (whatever the degree) (66, 67) and hypocortisolism (54) may present with reduced quality of life and impaired cognitive function. The idea would be to develop patient-centred studies on QoL and psychological status that could be as informative as disease-centred ones (68). Finally, new insights on the expression of adrenal hormone receptors in various cells may suggest that some new organs or tissues could be possible targets of adrenal hormone-related comorbidities. For example, osteoporosis and hyperparathyroidism have recently been suggested to be a possible complication of aldosterone excess, in keeping with the presence of mineralocorticoid receptors on the surface of parathyroid cell surface (69).

CONCLUSIONS

The pathophysiology of adrenal diseases represents a challenging and still poorly investigated topic.

The field of research and new issues have to be better explored in the future. For example, some recent data point to the possible role of gut microbioma in modulating cortisol metabolism, due to the presence of 11 β -hydroxysteroid dehydrogenase activity that plays a pivotal role in glucocorticoid metabolism. As new 11-hydroxysteroid dehydrogenase microbial 11 β -hydroxysteroid dehydrogenase enzymes are continually being discovered, a new mechanistic study of their impacts in disease models could be developed (70). Likewise, the role of aberrant G-protein coupled hormone receptors (GPCR) in the pathogenesis of adrenal tumors has been investigated for many years. However, it is still a matter of debate whether aberrant GPCR expression is the initiating event or a consequence of the proliferative cascade underlying adrenal hyperplasia or tumorigenesis. Animal models suggest that a single inappropriate expression of a nonmutated GPCR gene is sufficient to initiate the process that leads to the formation of a benign adrenocortical lesion. On the other hand, other data support the idea that aberrant expression of one or more GPCRs and their ligands in adrenal tissues is a secondary rather than a primary event (71). Interestingly, very recent evidence from animal studies suggests that chronic stress in early life can induce persistent up-regulation of the HPA axis

REFERENCES

1. Chiodini I, Ramos-Rivera A, Marcus AO, Yau H. Adrenal Hypercortisolism: A Closer Look at Screening, Diagnosis, and Important Considerations of Different Testing Modalities. *J Endocr Soc* (2019) 3:1097–109. doi: 10.1210/je.2018-00382

that generates endocrine, metabolic, and somatic alterations similar to those found in ACTH-dependent human ACTH-dependent hypercortisolism (72).

The relationship between the activity of the HPA axis and stress-related diseases and mood disorders and their reciprocal influence has been studied in the past and is likely to continue to be studied in the future (7, 11, 73). This represents an interesting model of how the degree of cortisol secretion (although within the normal range) can contribute to the pathogenesis of chronic diseases. For example, some recent data suggest that, even in eucortisolemic patients, the individual degree of exposure to cortisol (also called cortisol milieu) may influence cardiovascular risk and that in obese eucortisolemic patients, the degree of cortisol secretion is an independent predictor of diabetes and hypertension (16). Furthermore, increased GC sensitivity due to sensitizing polymorphisms of GC receptors was shown to be associated with worse glycometabolic and lipid profiles in subjects without hypercortisolism. Likewise, in eucortisolemic patients with diabetes, modulation of 11 β HSD activity was found to improve diabetes control. Finally, a growing body of evidence suggests a positive relationship between physiological, yet higher, urinary cortisol levels and cardiovascular risk (25).

The field of adrenal endocrinology is expected to have a bright future, provided that we can change our approaches, leaving the inherited dogma that adrenal diseases are rare disorders, while increasing awareness that alterations in adrenal hormones could be found in several chronic disorders, also contributing to their pathogenesis.

ETHICS STATEMENT

Informed consent was obtained from patients for the publication of their photos and biochemical and clinical data.

AUTHOR CONTRIBUTIONS

LG: conceptualization, writing—original draft, and writing—review and editing. IC: conceptualization, writing—original draft, and writing—review and editing. All authors contributed to the article and approved the submitted version.

FUNDING

This study has been partially supported by the Istituto Auxologico Italiano, IRCCS (Grant 05C921 - PRECOR Study).

2. Giovanelli L, Aresta C, Favero V, Bonomi M, Cangiano B, Eller-Vainicher C, et al. Hidden Hypercortisolism: A Too Frequently Neglected Clinical Condition. *J Endocrinol Invest* (2021). doi: 10.1007/s40618-020-01484-2
3. Pang X, Shimizu A, Kurita S, Zankov DP, Takeuchi K, Yasuda-Yamahara M, et al. Novel Therapeutic Role for Dipeptidyl Peptidase III in the Treatment of

- Hypertension. *Hypertension* (2016) 68:630–41. doi: 10.1161/HYPERTENSIONAHA.116.07357
4. Chanson P, Guignat L, Goichot B, Chabre O, Samara Boustani D, Reynaud R, et al. Group 2: Adrenal Insufficiency: Screening Methods and Confirmation of Diagnosis. *Ann Endocrinol (Paris)* (2017) 78:495–511. doi: 10.1016/j.ando.2017.10.005
 5. Young WF, Calhoun DA, Lenders JWM, Stowasser M, Textor SC. Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement. *Endocr Rev* (2017) 38:103–22. doi: 10.1210/er.2017-00054
 6. Berardelli I, Serafini G, Cortese N, Fiaschè F, O'Connor RC, Pompili M. The Involvement of Hypothalamus–Pituitary–Adrenal (Hpa) Axis in Suicide Risk. *Brain Sci* (2020) 10:1–12. doi: 10.3390/brainsci10090653
 7. Carvalho AF, Solmi M, Sanches M, Machado MO, Stubbs B, Ajnakina O, et al. Evidence-Based Umbrella Review of 162 Peripheral Biomarkers for Major Mental Disorders. *Transl Psychiatry* (2020) 18:152–65. doi: 10.1038/s41398-020-0835-5
 8. Lyraki R, Schedl A. Adrenal Cortex Renewal in Health and Disease. *Nat Rev Endocrinol* (2021) 17:421–34. doi: 10.1038/s41574-021-00491-4
 9. Siggelkow H, Etmanski M, Bozkurt S, Groß P, Koepf R, Brockmüller J, et al. Genetic Polymorphisms in 11 β -Hydroxysteroid Dehydrogenase Type 1 Correlate With the Postdexamethasone Cortisol Levels and Bone Mineral Density in Patients Evaluated for Osteoporosis. *J Clin Endocrinol Metab* (2014) 99:293–302. doi: 10.1210/jc.2013-1418
 10. Sigalas PD, Garg H, Watson S, McAllister-Williams RH, Ferrier N. Metyrapone in Treatment-Resistant Depression. *Ther Adv Psychopharmacol* (2012) 2:139–49. doi: 10.1177/2045125312436597
 11. Lombardo G, Enache D, Gianotti L, Schatzberg AF, Young AH, Pariante CM, et al. Baseline Cortisol and the Efficacy of Antiglucocorticoid Treatment in Mood Disorders: A Meta-Analysis. *Psychoneuroendocrinology* (2019) 110:104420. doi: 10.1016/j.psyneuen.2019.104420
 12. Chamarthi B, Kolatkar NS, Hunt SC, Williams JS, Seely EW, Brown NJ, et al. Urinary Free Cortisol: An Intermediate Phenotype and a Potential Genetic Marker for a Salt-Resistant Subset of Essential Hypertension. *J Clin Endocrinol Metab* (2007) 92:1340–6. doi: 10.1210/jc.2006-2093
 13. Isidori AM, Graziadio C, Paragliola RM, Cozzolino A, Ambrogio AG, Colao A, et al. The Hypertension of Cushing's Syndrome: Controversies in the Pathophysiology and Focus on Cardiovascular Complications. *J Hypertens* (2015) 33:44–60. doi: 10.1097/HJH.0000000000000415
 14. Morelli V, Polledri E, Mercadante R, Zhukouskaya VV, Palmieri S, Beck-Peccoz P, et al. The Activity of 11 β -Hydroxysteroid Dehydrogenase Type 2 Enzyme and Cortisol Secretion in Patients With Adrenal Incidentalomas. *Endocrine* (2016) 53:809–15. doi: 10.1007/s12020-015-0763-y
 15. Morgan SA, McCabe EL, Gathercole LL, Hassan-Smith ZK, Larner DP, Bujalska IJ, et al. 11 β -HSD1 Is the Major Regulator of the Tissue-Specific Effects of Circulating Glucocorticoid Excess. *Proc Natl Acad Sci USA* (2014) 111:E2482–91. doi: 10.1073/pnas.1323681111
 16. Chiodini I, Gaudio A, Eller-Vainicher C, Morelli V, Aresta C, Zhukouskaya VV, et al. Cortisol Secretion, Sensitivity, and Activity Are Associated With Hypertension in Postmenopausal Eucortisolemic Women. *J Clin Endocrinol Metab* (2019) 104:4441–8. doi: 10.1210/jc.2019-00037
 17. Zhukouskaya VV, Eller-Vainicher C, Gaudio A, Cairoli E, Olivieri FM, Palmieri S, et al. In Postmenopausal Female Subjects With Type 2 Diabetes Mellitus, Vertebral Fractures Are Independently Associated With Cortisol Secretion and Sensitivity. *J Clin Endocrinol Metab* (2015) 100:1417–25. doi: 10.1210/jc.2014-4177
 18. Koper JW, Van Rossum EFC, Van Den Akker ELT. Glucocorticoid Receptor Polymorphisms and Haplotypes and Their Expression in Health and Disease. *Steroids* (2014) 92:62–73. doi: 10.1016/j.steroids.2014.07.015
 19. Tabarin A, Perez P. Pros and Cons of Screening for Occult Cushing Syndrome. *Nat Rev Endocrinol* (2011) 7:445–55. doi: 10.1038/nrendo.2011.51
 20. Ronchi CL, Di Dalmazi G, Faillot S, Sberia S, Assié G, Weigand I, et al. Genetic Landscape of Sporadic Unilateral Adrenocortical Adenomas Without PRKACA P.Leu206Arg Mutation. *J Clin Endocrinol Metab* (2016) 101:3526–38. doi: 10.1210/jc.2016-1586
 21. Zennaro MC, Boulkroun S, Fernandes-Rosa F. Genetic Causes of Functional Adrenocortical Adenomas. *Endocrine Rev* (2017) 38:516–37. doi: 10.1210/er.2017-00189
 22. Ebbelohj A, Stochholm K, Jacobsen SF, Trolle C, Jepsen P, Robaczky MG, et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: A Population-Based Study. *J Clin Endocrinol Metab* (2021) 106:e2251–61. doi: 10.1210/clinem/dgaa965
 23. Betterle C, Presotto F, Furmaniak J. Epidemiology, Pathogenesis, and Diagnosis of Addison's Disease in Adults. *J Endocrinol Invest* (2019) 42:1407–33. doi: 10.1007/s40618-019-01079-6
 24. Ghayee HK, Vinik AI, Pacak KAACE Adrenal Scientific Committee. Precision Medicine in Adrenal Disorders: The Next Generation. *Endocr Pract* (2019) 176:139–48. doi: 10.4158/EP161716.RA
 25. Aresta C, Favero V, Morelli V, Giovannelli L, Parazzoli C, Falchetti A, et al. Cardiovascular Complications of Mild Autonomous Cortisol Secretion. *Best Pract Res Clin Endocrinol Metab* (2021) 101494. doi: 10.1016/j.beem.2021.101494
 26. Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* (2016) 101:1889–916. doi: 10.1210/jc.2015-4061
 27. Buonacera A, Stancanelli B, Malatino L. Endocrine Tumors Causing Arterial Hypertension: Pathophysiological Mechanisms and Clinical Implications. *High Blood Press Cardiovasc Prev* (2017) 24:217–29. doi: 10.1007/s40292-017-0200-9
 28. Bancos I, Alahdab F, Crowley RK, Chortis V, Delivanis DA, Erickson D, et al. Improvement of Cardiovascular Risk Factors After Adrenalectomy in Patients With Adrenal Tumors and Subclinical Cushing's Syndrome: A Systematic Review and Meta-Analysis. *Eur J Endocrinol* (2016) 175:R283–95. doi: 10.1530/EJE-16-0465
 29. Chiodini I, Mascia ML, Muscarella S, Battista C, Minisola S, Arosio M, et al. Subclinical Hypercortisolism Among Outpatients Referred for Osteoporosis. *Ann Intern Med* (2007) 147:541–8. doi: 10.7326/0003-4819-147-8-200710160-00006
 30. Chiodini I, Albani A, Ambrogio AG, Campo M, De Martino MC, Marcelli G, et al. Six Controversial Issues on Subclinical Cushing's Syndrome. *Endocrine* (2017) 56:262–6. doi: 10.1007/s12020-016-1017-3
 31. Aresta C, Soranna D, Giovannelli L, Favero V, Parazzoli C, Gennari L, et al. Endocrine Practice When to Suspect Hidden Hypercortisolism in Type 2 Diabetes: A Meta-Analysis. *Endocr Pract* (2021). doi: 10.1016/j.eprac.2021.07.014
 32. Hattersley R, Nana M, Lansdown AJ. Endocrine Complications of Immunotherapies: A Review. *Clin Med J R Coll Physicians London* (2021) 2:e212–22. doi: 10.7861/clinmed.2020-0827
 33. Eller-Vainicher C, Morelli V, Aresta C, Salcuni AS, Falchetti A, Carnevale V, et al. Defining Nonfunctioning Adrenal Adenomas on the Basis of the Occurrence of Hypocortisolism After Adrenalectomy. *J Endocr Soc* (2020) 4(8):bvaa079. doi: 10.1210/jendso/bvaa079
 34. de Paula MP, Moraes AB, de Souza M das GC, Cavalari EMR, Campbell RC, da Silva G, et al. Cortisol Level After Dexamethasone Suppression Test in Patients With Non-Functioning Adrenal Incidentaloma Is Positively Associated With the Duration of Reactive Hyperemia Response on Microvascular Bed. *J Endocrinol Invest* (2021) 44:609–19. doi: 10.1007/s40618-020-01360-z
 35. Elhassan YS, Alahdab F, Prete A, Delivanis DA, Khanna A, Prokop L, et al. Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess: A Systematic Review and Meta-Analysis. *Ann Intern Med* (2019) 171:107–16. doi: 10.7326/M18-3630
 36. Morelli V, Palmieri S, Lania A, Tresoldi A, Corbetta S, Cairoli E, et al. Cardiovascular Events in Patients With Mild Autonomous Cortisol Secretion: Analysis With Artificial Neural Networks. *Eur J Endocrinol* (2017) 177:73–83. doi: 10.1530/EJE-17-0047
 37. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, et al. Management of Adrenal Incidentalomas: European Society of Endocrinology Clinical Practice Guideline in Collaboration With the European Network for the Study of Adrenal Tumors. *Eur J Endocrinol* (2016) 175:G1–34. doi: 10.1530/EJE-16-0467
 38. Chiodini I, Morelli V. Subclinical Hypercortisolism: How to Deal With It? *Front Horm Res* (2016) 46:28–38. doi: 10.1159/000443862
 39. Grassi G, Morelli V, Ceriotti F, Polledri E, Fustinoni S, D'Agostino S, et al. Minding the Gap Between Cortisol Levels Measured With Second-Generation Assays and Current Diagnostic Thresholds for the Diagnosis of Adrenal

- Insufficiency: A Single-Center Experience. *Hormones* (2020) 19:425–31. doi: 10.1007/s42000-020-00185-y
40. Grassi G, Morelli V, Polledri E, Chiodini I, Ceriotti F, D'Agostino S, et al. Assessment of Biochemical Hyperandrogenism in PCOs by Liquid Chromatography Tandem Mass Spectrometry Using a Multiteroid Kit: Focus on Testosterone and Androstenedione. *J Clin Med* (2020) 10:119–28. doi: 10.3390/jcm10010119
 41. Casals G, Hanzu FA. Cortisol Measurements in Cushing's Syndrome: Immunoassay or Mass Spectrometry? *Ann Lab Med* (2020) 40:285–96. doi: 10.3343/alm.2020.40.4.285
 42. Di Dalmazi G, Fanelli F, Zavatta G, Ricci Bitti S, Mezzullo M, Repaci A, et al. The Steroid Profile of Adrenal Incidentalomas: Subtyping Subjects With High Cardiovascular Risk. *J Clin Endocrinol Metab* (2019) 104:5519–28. doi: 10.1210/jc.2019-00365
 43. Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, et al. Urine Steroid Metabolomics for the Differential Diagnosis of Adrenal Incidentalomas in the EURINE-ACT Study: A Prospective Test Validation Study. *Lancet Diabetes Endocrinol* (2020) 8:773–81. doi: 10.1016/S2213-8587(20)30218-7
 44. Pearce SHS, Gan EH, Napier C. Residual Adrenal Function in Addison's Disease. *Eur J Endocrinol* (2021) 184:R61–7. doi: 10.1530/EJE-20-0894
 45. Morelli V, Aresta C, Gaudio A, Eller-Vainicher C, Zhukouskaya VV, Merlotti D, et al. Prediction of Hypertension, Diabetes and Fractures in Eucortisolemic Women by Measuring Parameters of Cortisol Milieu. *Endocrine* (2020) 68:411–9. doi: 10.1007/s12020-020-02212-9
 46. Villa JEL, García I, Jimenez de Aberasturi D, Pavlova V, Sotomayor MDPT, Liz-Marzán LM. SERS-Based Immunoassay for Monitoring Cortisol-Related Disorders. *Biosens Bioelectron* (2020) 165:112418. doi: 10.1016/j.bios.2020.112418
 47. Świątkowska-Stodulska R, Berlińska A, Stefańska K, Klosowski P, Sworczak K. Cyclic Cushing's Syndrome – A Diagnostic Challenge. *Front Endocrinol (Lausanne)* (2021) 12:1–7. doi: 10.3389/fendo.2021.658429
 48. Stalder T, Stuedte-Schmiedgen S, Alexander N, Klucken T, Vater A, Wichmann S, et al. Stress-Related and Basic Determinants of Hair Cortisol in Humans: A Meta-Analysis. *Psychoneuroendocrinology* (2017) 77:261–74. doi: 10.1016/j.psyneuen.2016.12.017
 49. Phillips R, Kraeuter AK, McDermott B, Lupien S, Sarnyai Z. Human Nail Cortisol as a Retrospective Biomarker of Chronic Stress: A Systematic Review. *Psychoneuroendocrinology* (2021) 123:104903. doi: 10.1016/j.psyneuen.2020.104903
 50. Loerz C, Maser E. The Cortisol-Activating Enzyme 11 β -Hydroxysteroid Dehydrogenase Type 1 in Skeletal Muscle in the Pathogenesis of the Metabolic Syndrome. *J Steroid Biochem Mol Biol* (2017) 174:65–71. doi: 10.1016/j.jsbmb.2017.07.030
 51. Moraitis AG, Block T, Nguyen D, Belanoff JK. The Role of Glucocorticoid Receptors in Metabolic Syndrome and Psychiatric Illness. *J Steroid Biochem Mol Biol* (2017) 165:114–20. doi: 10.1016/j.jsbmb.2016.03.023
 52. Alrezk R, Suarez A, Tena I, Pacak K. Update of Pheochromocytoma Syndromes: Genetics, Biochemical Evaluation, and Imaging. *Front Endocrinol (Lausanne)* (2018) 9:1–13. doi: 10.3389/fendo.2018.00515
 53. Granberg D, Juhlin CC, Falhammar H. Metastatic Pheochromocytomas and Abdominal Paragangliomas. *J Clin Endocrinol Metab* (2021) 106:e1937–52. doi: 10.1210/clinem/dgaa982
 54. Husebye ES, Pearce SH, Krone NP, Kämpe O. Adrenal Insufficiency. *Lancet* (2021) 397:613–29. doi: 10.1016/S0140-6736(21)00136-7
 55. Tumors A, Tsoli M, Daskalakis K, Kaltsas G, Tsolakias AV. A Critical Appraisal of Contemporary and Novel Biomarkers in Pheochromocytomas and Adrenocortical Tumors. (2021) 1–14. doi: 10.3390/biology10070580
 56. Nanba K, Rainey WE. Race, Sex, and Genetic Causes of APA Genetics in Endocrinology Impact of Race and Sex on Genetic Causes of Aldosterone-Producing Adenomas. *Eur J Endocrinol* (2021) 85:1:R1–11. doi: 10.1530/EJE-21-0031
 57. Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and Treatment of Primary Aldosteronism. *Nat Rev Endocrinol* (2020) 16:578–89. doi: 10.1038/s41574-020-0382-4
 58. Albano D, Agnello F, Midiri F, Pecoraro G, Bruno A, Alongi P, et al. Imaging Features of Adrenal Masses. *Insights Imaging* (2019) 10:1–16. doi: 10.1186/s13244-019-0688-8
 59. Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, et al. Consensus on Molecular Imaging and Theranostics in Neuroendocrine Neoplasms. *Eur J Cancer* (2021) 146:56–73. doi: 10.1016/j.ejca.2021.01.008
 60. Cardenas SMC, Santhanam P. 1 C-Metomidate PET in the Diagnosis of Adrenal Masses and Primary Aldosteronism: A Review of the Literature. *Endocrine* (2020) 70:479–87. doi: 10.1007/s12020-020-02474-3
 61. Varlamov EV, Langlois F, Vila G, Fleseriu M. Cardiovascular Risk Assessment, Thromboembolism, and Infection Prevention in Cushing's Syndrome: A Practical Approach. *Eur J Endocrinol* (2021) 184:R207–24. doi: 10.1530/EJE-20-1309
 62. Varlamov EV, Han AJ, Fleseriu M. Updates in Adrenal Steroidogenesis Inhibitors for Cushing's Syndrome – A Practical Guide. *Best Pract Res Clin Endocrinol Metab* (2021) 35:101490. doi: 10.1016/j.beem.2021.101490
 63. Pivonello R, Ferrigno R, De Martino MC, Simeoli C, Di Paola N, Pivonello C, et al. Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. *Front Endocrinol (Lausanne)* (2020) 11:648. doi: 10.3389/fendo.2020.00648
 64. Auchus RJ, Sarafoglou K, Fechner PY, Vogiatzi M, Giri N, Roberts E, et al. The Effects of Crinicerfont (NBI-74788), a Novel CRF1 Receptor Antagonist, on Adrenal Androgens and Precursors in Patients With Classic Congenital Adrenal Hyperplasia: Results From A Multiple-Dose Phase 2 Study. *J Endo Soc* (2020) 4(Suppl 1):OR25–03. doi: 10.1210/jendso/bvaa046.221
 65. Pegna GJ, Roper N, Kaplan RN, Bergsland E, Kiseljak-Vassiliades K, Habra MA, et al. The Immunotherapy Landscape in Adrenocortical Cancer. *Cancers (Basel)* (2021) 13:2660–75. doi: 10.3390/cancers13112660
 66. Pivonello R, Isidori AM, De Martino MC, Newell-Price J, Biller BMK, Colao A, et al. Complications of Cushing's Syndrome: State of the Art. *Lancet Diabetes Endocrinol* (2016) 4:611–29. doi: 10.1016/S2213-8587(16)00086-3
 67. Morelli V, Ghielmetti A, Caldiroli A, Grassi S, Siri FM, Caletti E, et al. Mental Health in Patients With Adrenal Incidentalomas: Is There a Relation With Different Degrees of Cortisol Secretion? *J Clin Endocrinol Metab* (2020) 106:e130–95. doi: 10.1210/clinem/dgaa695
 68. Valassi E, Tabarin A, Chiodini I, Feelders R, Andela C. The Cushing's Collaborative Patient Survey Results. *European Congress Endocrin* (2020).
 69. Salcuni AS, Carnevale V, Battista C, Palmieri S, Eller-Vainicher C, Guarnieri V, et al. Primary Aldosteronism as a Cause of Secondary Osteoporosis. *Eur J Endocrinol* (2017) 177:431–7. doi: 10.1530/EJE-17-0417
 70. Doden HL, Ridlon JM. Microbial Hydroxysteroid Dehydrogenases: From Alpha to Omega. *Microorganisms* (2021) 9:1–24. doi: 10.3390/microorganisms9030469
 71. El Ghorayeb N, Bourdeau I, Lacroix A. Multiple Aberrant Hormone Receptors in Cushing's Syndrome. *Eur J Endocrinol* (2015) 173:M45–60. doi: 10.1530/EJE-15-0200
 72. Campana G, Loizzo S, Fortuna A, Rimondini R, Maroccia Z, Scillitani A, et al. Early Post-Natal Life Stress Induces Permanent Adrenocorticotropin-Dependent Hypercortisolism in Male Mice. *Endocrine* (2021) 73:186–95. doi: 10.1007/s12020-021-02659-4
 73. Bao AM, Swaab DF. The Human Hypothalamus in Mood Disorders: The HPA Axis in the Center. *IBRO Rep* (2019) 6:45–53. doi: 10.1016/j.ibror.2018.11.008

Conflict of Interest: LG has no financial relationships with any organization that might have an interest in the submitted work and no other relationships or activities that could appear to have influenced the submitted work.

IC is an investigator in relacorilant studies (Corcept Therapeutics) in patients with hypercortisolism and received consulting fees from Corcept Therapeutics and HRA Pharma.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Chiodini and Gennari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.